Thalidomide in the treatment of relapsed multiple myeloma

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Objective: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. Patients and Methods: We studied 16 patients (median age, 64 years), who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. Results: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. Conclusion: Thalidomide is an active agent in the treatment of patients with advanced myeloma.

Original languageEnglish (US)
Pages (from-to)897-901
Number of pages5
JournalMayo Clinic Proceedings
Volume75
Issue number9
StatePublished - 2000

Fingerprint

Thalidomide
Multiple Myeloma
Therapeutics
Salmon
Stem Cell Transplantation
Peripheral Nervous System Diseases
Constipation
Exanthema
Urine
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thalidomide in the treatment of relapsed multiple myeloma. / Rajkumar, S Vincent; Fonseca, Rafael; Dispenzieri, Angela; Lacy, Martha; Lust, John A.; Witzig, Thomas Elmer; Kyle, Robert A.; Gertz, Morie; Greipp, Philip R.

In: Mayo Clinic Proceedings, Vol. 75, No. 9, 2000, p. 897-901.

Research output: Contribution to journalArticle

@article{381b6abab44d43a8b4da517b469933e6,
title = "Thalidomide in the treatment of relapsed multiple myeloma",
abstract = "Objective: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. Patients and Methods: We studied 16 patients (median age, 64 years), who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. Results: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56{\%}) and IIIB in 7 (44{\%}). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25{\%}) prior stem cell transplantation had failed, and 14 (88{\%}) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25{\%}) achieved a partial response to therapy, with a greater than 50{\%} reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. Conclusion: Thalidomide is an active agent in the treatment of patients with advanced myeloma.",
author = "Rajkumar, {S Vincent} and Rafael Fonseca and Angela Dispenzieri and Martha Lacy and Lust, {John A.} and Witzig, {Thomas Elmer} and Kyle, {Robert A.} and Morie Gertz and Greipp, {Philip R.}",
year = "2000",
language = "English (US)",
volume = "75",
pages = "897--901",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Thalidomide in the treatment of relapsed multiple myeloma

AU - Rajkumar, S Vincent

AU - Fonseca, Rafael

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Lust, John A.

AU - Witzig, Thomas Elmer

AU - Kyle, Robert A.

AU - Gertz, Morie

AU - Greipp, Philip R.

PY - 2000

Y1 - 2000

N2 - Objective: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. Patients and Methods: We studied 16 patients (median age, 64 years), who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. Results: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. Conclusion: Thalidomide is an active agent in the treatment of patients with advanced myeloma.

AB - Objective: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. Patients and Methods: We studied 16 patients (median age, 64 years), who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. Results: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. Conclusion: Thalidomide is an active agent in the treatment of patients with advanced myeloma.

UR - http://www.scopus.com/inward/record.url?scp=0033815863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033815863&partnerID=8YFLogxK

M3 - Article

C2 - 10994824

AN - SCOPUS:0033815863

VL - 75

SP - 897

EP - 901

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -